Everolimus in ileum neuroendocrine tumours
- PMID: 27479567
- DOI: 10.1016/S0140-6736(16)31039-X
Everolimus in ileum neuroendocrine tumours
Comment in
-
Everolimus in ileum neuroendocrine tumours - Authors' reply.Lancet. 2016 Jul 16;388(10041):236-7. doi: 10.1016/S0140-6736(16)31045-5. Lancet. 2016. PMID: 27479568 No abstract available.
Comment on
-
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. Lancet. 2016. PMID: 26703889 Free PMC article. Clinical Trial.
Similar articles
-
Everolimus in ileum neuroendocrine tumours - Authors' reply.Lancet. 2016 Jul 16;388(10041):236-7. doi: 10.1016/S0140-6736(16)31045-5. Lancet. 2016. PMID: 27479568 No abstract available.
-
Universal everolimus for malignant neuroendocrine tumours?Lancet. 2016 Mar 5;387(10022):924-926. doi: 10.1016/S0140-6736(15)01234-9. Epub 2015 Dec 17. Lancet. 2016. PMID: 26703890 No abstract available.
-
Everolimus Effectively Treats Neuroendocrine Tumors of Gut and Lungs.J Natl Cancer Inst. 2016 Jul 2;108(7):djw175. doi: 10.1093/jnci/djw175. Print 2016 Jul. J Natl Cancer Inst. 2016. PMID: 27371861 No abstract available.
-
Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis.Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 7):11-3. Clin Adv Hematol Oncol. 2016. PMID: 27168106 Review. No abstract available.
-
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.Clin Adv Hematol Oncol. 2014 Dec;12(12 Suppl 19):3-5. Clin Adv Hematol Oncol. 2014. PMID: 25768101 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical